A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

Inclusion Criteria

• •Moderately to severely active Ulcerative Colitis (UC) diagnosed prior to the Screening Visit
• •Evidence of UC extending beyond the rectum, as determined by baseline endoscopy
• •Has had an inadequate response, loss of response to, or is intolerant to at least 1 of the following treatments for UC: oral aminosalicylates, systemic corticosteroids, immunomodulators, biologic therapy